Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
The aim of study is to assess the angioprotective effects of antihypertensive combination
therapy with perindopril 10 mg and moxonidine 0.4-0.6 mg in patients with arterial
hypertension, metabolic syndrome, and obesity, who had Pulse Wave Velocity (PWV) > 10 m/s on
the previously administered two-component combination antihypertensive therapy.
Open-label non-comparative prospective study for 24 week for each patient.